Literature DB >> 24064787

Work-related and health care cost burden of community-acquired pneumonia in an employed population.

Nathan L Kleinman1, Holly Yu, Ian A Beren, Reiko Sato.   

Abstract

OBJECTIVE: To estimate community-acquired pneumonia (CAP) incidence, turnover, episode length, inpatient length-of-stay, and cost burden.
METHODS: Using 2007 to 2010 employee demographic, payroll, and claims data, CAP episodes were identified in employees aged 18 to 64 years. Semiannual medical, drug, sick leave, short-term disability (STD), long-term disability, and workers' compensation costs and absence days were compared between employees with and without CAP (controls) using two-part regression modeling.
RESULTS: In a population of 250,000, the number of CAP episodes per 100,000 employees was 628. The incidence rate increased with age and comorbidity. CAP employees' turnover rate nearly doubled that of controls (P < 0.01). In every age and risk group, employees with CAP had significantly (P < 0.01) higher medical and drug costs than controls and double the STD costs and days (P < 0.05).
CONCLUSIONS: CAP and underlying comorbidity are associated with increased medical, pharmacy, and STD costs and employee turnover rates.

Entities:  

Mesh:

Year:  2013        PMID: 24064787     DOI: 10.1097/JOM.0b013e3182a7e6af

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  3 in total

1.  Pneumococcal Vaccination Among Adults With Work-related Asthma.

Authors:  Katelynn E Dodd; Jacek M Mazurek
Journal:  Am J Prev Med       Date:  2017-09-27       Impact factor: 5.043

Review 2.  Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.

Authors:  Antoni Torres; Francesco Blasi; Nathalie Dartois; Murat Akova
Journal:  Thorax       Date:  2015-07-28       Impact factor: 9.139

3.  Risk of exacerbation following pneumonia in adults with heart failure or chronic obstructive pulmonary disease.

Authors:  Rebecca Bornheimer; Kimberly M Shea; Reiko Sato; Derek Weycker; Stephen I Pelton
Journal:  PLoS One       Date:  2017-10-13       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.